
Impact Note

30 November 2021

Price as of 29/11/21: €65.45



Heading for EUR230m in EBITDA



Share data	
Reuters	VBKG.DE
No. of shares (m)	63.0
Daily volume (3m)	135,183
Free float	28.4%
Market cap. (m)	4,123.4
EV (m)	4,107.6
Sales CAGR 18-22e	13.5%

Valuation	21/22e	22/23e
EV/Sales	2.9	3.2
EV/ EBITDA	17.7	22.0
EV/EBIT	20.7	27.3
PER	29.9	39.4
Div. yield	0.4%	0.4%
RoCE	32.8%	21.5%
RoE	21.7%	14.5%

Analysts
Hartmut Moers
Tel.: +49 228 227 99 240
hartmut.moers@matelan.de

Investment case

Verbio has raised its FY guidance clearly above our estimate and we have adjusted our FY 21/22 forecast accordingly. So far, we only price in the addition for this one year so that our fair value rises only to EUR80.5. If this effect turns out to be sustainable, we will add another EUR6 to our valuation. Newsflow should remain positive, from the upcoming results and projects that are not yet included in our estimates. Against this background, we clearly reiterate our BUY rating on the stock.

FY GUIDANCE RAISED

In view of current pricing for Biodiesel and Bioethanol, Verbio has raised its full year EBITDA guidance to EUR230m (from EUR150m). Net cash should come to EUR80m by year end (from EUR50m). This assumes no hard Covid-19 restrictions.

BEATING EXPECTATION

At the Q1 stage, we had said that based on the forward curve at the time we would expect the company to beat its guidance and reach EUR200m in EBITDA. Now prices have come down slightly from the level at the beginning of November and management plans even EUR30m more than we had anticipated. This might well be a structural effect that could translate into future periods.

INCREASE IN EARNINGS AND FAIR VALUE


We raise our full year EBITDA estimate to around EUR230m, which assumes Q3 and Q4 to match the result of the first quarter while the upcoming Q2 should remain extraordinarily strong. We do not yet change our estimates for the following years, so that our fair value comes up to just EUR80.5. However, if the earnings increase results from an improved earnings structure we will add another EUR6 to our valuation.

For additional disclosures please refer to the appendix


	1		1.1		
Forecasts	18/19	19/20	20/21	21/22e	22/23e
Sales (€m)	779.3	872.4	1026.4	1430.4	1291.6
EBITDA (€m)	95.1	122.1	166.3	231.7	187.4
EBIT (€m)	73.7	91.9	136.6	198.7	151.4
Adj. EPS (€)	0.84	1.01	1.48	2.19	1.66
Dividend (€)	0.20	0.20	0.20	0.25	0.25
Oper. CF (€m)	44.3	71.7	117.2	123.1	159.5
Free CF (€m)	-18.7	3.7	50.1	-26.9	9.5


MATELAN Research







In EURm





In EURm







EURm	2018/19	2019/20	2020/21	2021/22e 2	2022/23e
Sales	779.3	872.4	1,026.4	1,430.4	1,291.6
Growth		11.9%	17.6%	39.4%	-9.7%
Material costs	-618.4	-673.5	-754.4	-1,100.7	-989.2
Gross profit	160.9	198.9	272.0	329.7	302.4
Gross margin	20.7%	22.8%	26.5%	23.0%	23.4%
Other operating costs	-28.6	-31.9	-51.2	-41.0	-56.0
EBITDA	95.1	122.1	166.3	231.7	187.4
Margin	12.2%	14.0%	16.2%	16.2%	14.5%
Depreciation	-21.4	-30.2	-29.7	-33.0	-36.0
EBIT	73.7	91.9	136.6	198.7	151.4
Margin	9.5%	10.5%	13.3%	13.9%	11.7%
Financial result	-0.6	-0.9	-1.3	-1.5	-1.
EBT	73.1	91.0	135.4	197.2	149.
Taxes	-21.4	-27.2	-41.8	-59.2	-44.9
Net profit	51.7	63.8	93.5	138.0	104.8
Minorities / Discon. Op.	1.1	-0.4	-0.3	-0.2	-0.2
Net profit a.m.	52.8	63.4	93.2	137.8	104.0
Growth	n.m.	n.m.	n.m.	n.m.	n.m
No of shares	63.0	63.0	63.0	63.0	63.0
EPS	0.84	1.01	1.48	2.19	1.60
Adj. EPS	0.84	1.01	1.48	2.19	1.6
Growth	n.m.	n.m.	n.m.	n.m.	n.m
Dividend	0.20	0.20	0.20	0.25	0.2

Balance Sheet					
EURm	2018/19	2019/20	2020/21	2021/22e 2	2022/23e
Intangible assets	0.9	0.7	0.6	0.6	0.6
Tangible assets	209.3	267.6	306.8	423.8	537.8
Participations	0.1	2.8	2.8	2.8	2.8
Other non-current assets	3.9	2.7	2.1	5.8	6.8
Non-current assets	214.2	273.8	312.3	433.0	548.0
Inventories	63.1	78.8	101.5	141.4	127.7
Receivables	48.5	64.7	69.6	96.9	87.5
Cash	63.1	73.9	105.0	45.0	20.0
Other current assets	36.1	38.1	90.3	42.0	42.0
Current Assets	210.8	255.4	366.3	325.4	277.3
Total assets	424.9	529.2	678.6	758.4	825.3
Equity	339.2	389.1	507.8	633.3	722.3
Minorities	-0.3	1.7	2.0	2.0	2.0
Total equity	338.9	390.8	509.9	635.3	724.3
LT financial liabilities	0.1	30.1	30.0	30.0	30.0
Pension provisions	0.2	0.1	0.1	0.1	0.1
OtherLT liabilities	6.9	19.1	15.3	19.0	19.0
Non-current liabilities	7.1	49.3	45.5	49.1	49.1
ST financial liabilities	10.0	0.1	0.0	0.0	0.0
Payables	41.3	41.1	45.4	63.2	57.1
Other ST liabilities	27.6	47.8	77.9	10.8	-5.3
Current liabilities	78.9	89.1	123.3	74.0	51.8
Total liabilities	424.9	529.2	678.6	758.4	825.3

EURm	2018/19	2019/20	2020/21	2021/22e 2	022/236
EBIT	73.7	91.9	136.6	198.7	151.4
Depreciation	21.4	30.2	29.7	33.0	36.0
Other non-cash items	-13.4	-3.2	19.5	0.0	0.0
Cash taxes	-25.2	-13.5	-44.5	-59.2	-44.9
Cash earnings	56.5	105.3	141.4	172.5	142.5
Change in NWC	-12.2	-33.7	-24.2	-49.5	17.0
CF from operations	44.3	71.7	117.2	123.1	159.5
Capex	-63.0	-68.0	-67.1	-150.0	-150.0
Other investm./divestm.	2.0	0.3	0.1	0.0	0.0
CF from investing	-61.0	-67.7	-66.9	-150.0	-150.0
CF from fin. and other	-8.8	6.8	-19.1	-33.1	-34.5
Change in cash	-25.5	10.8	31.1	-60.0	-25.0

Segments and adjusted earnings					
EURm	2018/19	2019/20	2020/21	2021/22e 2	2022/23e
Biodiesel	514.5	588.2	729.9	1,066.5	932.0
Bioethanol/-methan	254.7	275.2	286.6	352.6	347.5
Other	16.7	15.8	16.7	17.2	18.2
Consolidation	-6.6	-6.9	-6.8	-6.0	-6.0
Sales	779.3	872.4	1,026.4	1,430.4	1,291.6
Growth		11.9%	17.6%	39.4%	-9.7%
Biodiesel	70.7	46.1	93.2	142.4	104.7
Bioethanol/-methan	23.8	74.0	70.6	85.4	79.1
Other	0.6	2.0	2.5	3.9	3.7
Consolidation	0.0	0.0	0.0	0.0	0.0
EBITDA	95.1	122.1	166.3	231.7	187.4
Margin	12.2%	14.0%	16.2%	16.2%	14.5%

	2018/19	2019/20	2020/21	2021/22e	2022/23e
Share price	6.56	9.35	27.57	65.45	65.45
x No of shares	63.0	63.0	63.0	63.0	63.0
Market Capitalisation	413.3	589.1	1,736.9	4,123.4	4,123.4
+ Net financial debt	-53.0	-43.6	-75.0	-15.0	10.0
+ Pension provision	0.2	0.1	0.1	0.1	0.1
+ Minorities	-0.3	1.7	2.0	2.0	2.0
- Participations	-0.1	-2.8	-2.8	-2.8	-2.8
Enterprise Value	360.0	544.4	1,661.2	4,107.6	4,132.6
Sales	779.3	872.4	1,026.4	1,430.4	1,291.6
Adj. EBITDA	95.1	122.1	166.3	231.7	187.4
Adj. EBIT	73.7	91.9	136.6	198.7	151.4
Adj. Net profit a.m.	52.8	63.4	93.2	137.8	104.6
EV / Sales	0.5	0.6	1.6	2.9	3.2
EV / EBITDA	3.8	4.5	10.0	17.7	22.0
EV / EBIT	4.9	5.9	12.2	20.7	27.3
PE	7.8	9.3	18.6	29.9	39.4

	2018/19	2019/20	2020/21	2021/22e	2022/23e
Equity ratio	79.8%	73.9%	75.1%	83.8%	87.8%
Gearing	0.0	0.1	0.1	0.0	0.0
Asset turnover	3.6	3.2	3.3	3.3	2.4
NWC / sales	9.0%	11.7%	12.2%	12.2%	12.2%
Payable days outst.	19.4	17.2	16.1	16.1	16.1
Receivable days outst.	22.7	27.1	24.7	24.7	24.7
Fix operating assets	214.1	270.9	309.5	430.2	545.2
NWC	70.3	102.4	125.6	175.1	158.1
Capital employed	284.4	373.3	435.1	605.3	703.3
RoE	15.3%	16.3%	18.3%	21.7%	14.5%
RoA	17.3%	17.4%	20.1%	26.2%	18.4%
RoCE	25.9%	24.6%	31.4%	32.8%	21.5%
Gross margin	20.7%	22.8%	26.5%	23.0%	23.4%
EBITDA margin	12.2%	14.0%	16.2%	16.2%	14.5%
EBIT margin	9.5%	10.5%	13.3%	13.9%	11.7%
Net profit margin	6.8%	7.3%	9.1%	9.6%	8.1%

Source: Verbio, Matelan Research

ADDITIONAL DISCLOSURES

This report has been prepared by Matelan Research GmbH, Koblenzer Str. 79, 53177 Bonn. All rights are reserved. Copyrights and database rights protection exists in this publication. It may not be reproduced or redistributed without prior express permission of Matelan.

(1) Analyst certification

The analysts responsible for the content of this research report hereby certify that (1) all views expressed in this report accurately reflect their views about any and all of the subject securities or issuers and (2) no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or view(s) of this report.

Matelan may have sent extracts of this research report to the subject company for the purpose of verifying factual accuracy. The information provided by the latter was taken into consideration in the report. However, this entailed no change of the assessment.

(2) Disclosures about potential conflicts of interest

Matelan Research GmbH has/will receive(d) compensation for advisory services provided in the current calendar year from the company under review.

(3) Rating definitions

Security firms use a variety of rating terms and systems. Investors should carefully read the definitions of the rating system used in each research report. In addition, since the research report contains more complete information concerning analyst's views, investors should carefully read the entire research report and not infer its contents from the ratings alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

MATELAN Research GmbH uses an absolute rating system, which varies considerably from relative rating systems (such as "Overweight", "Equal Weight" or "Underweight"). Stock ratings are defined as follows:

Strong Buy:	In the next 6 to 12 months, we expect a potential absolute change in value of over 20% with high
	forecast certainty.
Buy:	In the next 6 to 12 months, we expect a potential absolute change in value of more than 10%.
Neutral:	In the next 6 to 12 months, we expect a potential absolute change in value of over 0% up to a maximum of 10%.
Reduce:	In the next 6 to 12 months, we expect a potential absolute negative change in value of up to -10%.
Sell:	In the next 6 to 12 months, we expect a potential absolute negative change in value of over -10 % with high forecast certainty.

The change in stock price results from the difference between the current share price and the analyst's performance expectations, which are generally based on a fair value calculation performed on the basis of a discounted cash flow model and a key comparison analysis but can also consider other effects such as market sentiment.

(4) Rating distribution

Stock ratings within the coverage universe of MATELAN Research GmbH as of the publication date of this report are distributed as follows:

Strong Buy:	0.0%
Buy:	62.5%
Neutral:	37.5%
Reduce:	0.0%
Sell:	0.0%

(5) Recommendation history

Stock ratings for the company covered in this report have developed as follows:

Verbio	
Date	Rating
12/12/18	Buy
09/11/18	Strong Buy
12/02/18	Buy
29/03/16	Neutral
05/02/15	Buy
10/02/12	Neutral

(6) Additional information for clients in Germany and other countries

This research report has been produced in Germany. It was approved and distributed by MATELAN Research GmbH, which is supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). Laws and regulations in other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. In particular, this document may not be distributed in the United States, Canada, Australia or Japan or to any U.S. person.

DISCLAIMER

This research publication has been prepared by MATELAN analysts based on publicly available data that is believed to be accurate and complete. While reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, MATELAN provides no representation or warranty in relation to its accuracy, completeness or reliability. Possible errors or incompleteness of the information do not constitute grounds for liability, either with regard to indirect or to direct or consequential damages. In particular, MATELAN is not liable for the statements, plans or other details contained in the information concerning the examined companies, strategies, economic situations, market and competitive situations, regulatory environment, etc.

Neither MATELAN nor its employees are liable for the accuracy and completeness of the statements, estimates and conclusions derived from the information contained in this report. To the extent this research report is being transmitted in connection with an existing contractual relationship, e.g. financial advisory or similar services, the liability of MATELAN shall be restricted to gross negligence and wilful misconduct. In any case, the liability of MATELAN is limited to typical, foreseeable damages and liability for any indirect damages is excluded.

This report does not constitute an offer to sell, or a solicitation of an offer to purchase, any security. MATELAN may perform services to other companies mentioned in this report. Directors or employees of MATELAN may serve on the board of directors of companies mentioned in this report. Any opinions contained herein are subject to change without notice.

The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. MATELAN does not accept any liability for any loss or damage out of the use of all or any part of this report. Additional information will be made available upon request.

Past performance is not necessarily indicative of future results. Investors should make their own investment decisions without relying on this publication. Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuers or market discussed herein and other persons should not take any action on the basis of this publication.

Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and not be suitable for all investors. The price of securities may decrease or increase and as a result investors may lose the amount originally invested. Changes in exchange rates may also cause the value of investments to decrease or increase. Any documents or information we provide is solely for informational purposes and directed only to persons we reasonably believe to be investment professionals.

All such communications and any activity to which they relate are available only to such investment professionals; any activity arising from such communications will only be carried out with investment professionals. Persons who do not have professional experience in matters relating to investments shout not rely upon such communications.

CONTACT DATA

For further information please contact:

Matelan Research GmbH	Head Analyst:
Koblenzer Straße 79	Hartmut Moers
53177 Bonn	Tel: +49 228 227 99 240
www.matelan.de	e-mail: hartmut.moers@matelan.de